Developer docs
API playgroundTry for free, no card

Search company profiles

Covaxx

Full company profile

uuid0000uq5

Namestring
Covaxx
Legal namestring
Vaxxinity Inc.
Websiteurl
covaxx.com
Company typeenum
Private
Founded yearint
2019
Short descriptiontext

Vaxxinity (formerly Covaxx) is a privately held biotech developing synthetic peptide-based vaccines and immunotherapies, led by the UB-612 COVID-19 booster that completed Phase III trials. It targets government health authorities and healthcare systems with a non-mRNA, cold-chain-independent platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCape Canaveral, United States
HQ citystring
Cape Canaveral
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
COVID-19 vaccines, peptide vaccines, vaccine development, biotech therapeutics, immunotherapy platform
Industry2 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
COVID-19 Vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Vaccine Product Sales
TypeOne Time License
Description

Revenue generated from sale of COVID-19 vaccine products (UB-612) to governments, healthcare providers, and procurement programs. One-time vaccination course revenue model typical of pharmaceutical vaccine products.

vaxxinity.com
2Clinical Development Partnerships
TypeLicensing Royalties
Description

Partnership funding from organizations like CEPI to co-fund Phase III clinical trials, providing non-dilutive capital for vaccine development in exchange for future supply commitments.

vaxxinity.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Covaxx (now operating as Vaxxinity) is a biotechnology company developing synthetic peptide-based vaccines, with its lead product being the UB-612 COVID-19 booster vaccine. The vaccine uses a non-mRNA, non-spike-protein approach that does not require frozen cold chain storage, enabling simpler and more cost-effective distribution. The company also maintains a computational pipeline for cross-reactive antibody discovery to support future vaccine and immunotherapy development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • High success rate in predicting candidate cross-reactive antibodies for multiple coronavirus variants
+1 more record
Product and service1 record
1UB-612 COVID-19 Booster Vaccine
CategoryVaccines
Description

A COVID-19 booster vaccine developed using a synthetic peptide-based platform rather than mRNA technology. It targets coronavirus antigens without using the spike protein, provides long-lasting protection against emerging variants, is well-tolerated, and remains stable at refrigerated (non-frozen) temperatures. Designed for governments, healthcare systems, and public vaccination programs seeking cost-effective, logistically simpler alternatives to mRNA vaccines.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Market position
Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Covaxx

COVID-19 Vaccinescovaxx.com

Vaxxinity (formerly Covaxx) is a privately held biotech developing synthetic peptide-based vaccines and immunotherapies, led by the UB-612 COVID-19 booster that completed Phase III trials. It targets government health authorities and healthcare systems with a non-mRNA, cold-chain-independent platform.

Covaxx firmographics

Firmographics
Name
Covaxx
Legal name
Vaxxinity Inc.
Website
https://covaxx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Vaxxinity (formerly Covaxx) is a privately held biotech developing synthetic peptide-based vaccines and immunotherapies, led by the UB-612 COVID-19 booster that completed Phase III trials. It targets government health authorities and healthcare systems with a non-mRNA, cold-chain-independent platform.
Ownership category
akta.pro rank

Covaxx industry classification

Industry
Product category
COVID-19 Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines

Keywords

  • COVID-19 vaccines
  • Peptide vaccines
  • Vaccine development
  • Biotech therapeutics
  • Immunotherapy platform

Where Covaxx is headquartered

Location

Headquarters

HQ city
Cape Canaveral
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Covaxx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Vaccine Product Sales: Revenue generated from sale of COVID-19 vaccine products (UB-612) to governments, healthcare providers, and procurement programs. One-time vaccination course revenue model typical of pharmaceutical vaccine products.
  2. Clinical Development Partnerships: Partnership funding from organizations like CEPI to co-fund Phase III clinical trials, providing non-dilutive capital for vaccine development in exchange for future supply commitments.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Covaxx product offering

Product offering

Core offering

Covaxx (now operating as Vaxxinity) is a biotechnology company developing synthetic peptide-based vaccines, with its lead product being the UB-612 COVID-19 booster vaccine. The vaccine uses a non-mRNA, non-spike-protein approach that does not require frozen cold chain storage, enabling simpler and more cost-effective distribution. The company also maintains a computational pipeline for cross-reactive antibody discovery to support future vaccine and immunotherapy development.

Differentiator

Problem solved

Functional benefit

Products and services

  • UB-612 COVID-19 Booster Vaccine A COVID-19 booster vaccine developed using a synthetic peptide-based platform rather than mRNA technology. It targets coronavirus antigens without using the spike protein, provides long-lasting protection against emerging variants, is well-tolerated, and remains stable at refrigerated (non-frozen) temperatures. Designed for governments, healthcare systems, and public vaccination programs seeking cost-effective, logistically simpler alternatives to mRNA vaccines.

Quantifiable outcome

  • High success rate in predicting candidate cross-reactive antibodies for multiple coronavirus variants
  • +1 more outcomes

Companies that use Covaxx

Customer profile

Segments2 records

Ideal customer profiles2 records

Covaxx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Covaxx partnerships and signals

Strategic signal

Scale indicators3 records

Covaxx competitors and assessment

Company assessment

Market position

Customer concentration

Covaxx social profiles

Digital presence

Covaxx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Covaxx leadership team

Management profile

Number of profiles

Profiles3 records

Covaxx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Covaxx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Covaxx

What does Covaxx do?

Covaxx (now operating as Vaxxinity) is a biotechnology company developing synthetic peptide-based vaccines, with its lead product being the UB-612 COVID-19 booster vaccine. The vaccine uses a non-mRNA, non-spike-protein approach that does not require frozen cold chain storage, enabling simpler and more cost-effective distribution. The company also maintains a computational pipeline for cross-reactive antibody discovery to support future vaccine and immunotherapy development.

Is Covaxx a public or private company?

Covaxx is a private company. It is classified as unknown and is currently operating.

When was Covaxx founded?

Covaxx was founded in 2019. It employs 51 to 100 people.

Where is Covaxx based?

Covaxx is headquartered in Cape Canaveral, United States, in the North America region.

How does Covaxx make money?

Two revenue lines are on record. Vaccine Product Sales are the primary driver. The others are clinical Development Partnerships.

Does Covaxx have an API?

No public API is recorded for Covaxx.

What industry is Covaxx in?

Covaxx's product category is COVID-19 Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaCovishield demand down under CovaxCovishield demand under the Covax facility has fallen to 0.4 million doses from an initial 5.4 million, as countries prefer mRNA vaccines or J&J. The drop follows unmet 2021 supply expectations and India's export suspension. J&J demand rose to 73.6 million, while AstraZeneca fell to 16.1 million.UNICEF DATACOVAX calls for urgent action to close vaccine equity gapCOVAX called on countries to set ambitious vaccination targets and close the global vaccine equity gap, citing low uptake in lower-income countries. Only 16% of people in low-income countries have received a single dose, versus 80% in high-income countries. COVAX has access to enough doses to protect 70% of populations in 91 lower-income countries.YahooUPDATE 1-COVAX, African Union decline to buy more doses of Moderna's COVID shotsCOVAX and the African Union declined to buy additional Moderna COVID-19 doses, opting out of 166 million doses for Q3 and Q4 2022. The global alliance, backed by Gavi and WHO, has delivered about 1.4 billion doses to 144 countries as of April 1, but faces cold-chain and funding gaps.Vanguard NewsCOVAX delivers 1bn COVID-19 vaccine dosesCOVAX delivered its one billionth COVID-19 vaccine dose to 144 countries, with shipments to poorer nations limited by supply shortages. Nigeria has administered over 17.5 million doses, and over 40% of the world's population has not received a first dose.trib.alCovax Reaches One Billion Shots Delivered to Poorer NationsCovax delivered over one billion Covid-19 shots to poorer nations, the WHO said. Deliveries have reached 144 countries, and the WHO noted the work remains incomplete.Business StandardCOVAX targets 70% Covid-19 immunisation coverage by mid next yearCOVAX set a target to achieve 70% COVID-19 immunization coverage by mid-2022, amid challenges from variant-specific vaccines and country preferences. The Independent Allocation of Vaccines Group validated only 730 million of 8 billion administered doses, urging manufacturers and high-coverage countries to prioritize equity and transparency.Arkansas Democrat-GazetteCovax initiative falls short on its '21 doses pledgeCovax, the UN-led vaccine-sharing initiative, has lowered its 2021 delivery target to 800 million doses, well below its original 2.3 billion pledge. As of November, 596 million doses had been delivered, requiring over 200 million more this month. Officials say the final number is uncertain, with some doses expected in early 2022.MarketWatchModerna boosts supply agreements with Covax, Gavi by 20 million doses this year and 20 million doses next yearModerna announced new supply agreements with Gavi and Covax, adding 20 million doses this year and 20 million next year. The deal raises Covax's 2021 supply to 54 million doses and Gavi's second-quarter supply to 136.5 million. Moderna's stock fell 12.9% in premarket trading.YahooSwiss strike deal for COVAX to get 1 million Moderna doses more quicklySwitzerland swapped places in the COVAX supply queue, allowing 1 million Moderna doses to go to the GAVI alliance in Q4 2021, with Switzerland receiving them later in 2022. GAVI urged other governments to slot-swap with manufacturers. COVAX has delivered about 507 million doses to 144 countries since February.The Times of IndiaSerum Institute gets nod to export vaccines to COVAXSerum Institute of India received approval to export 50 lakh doses of Covishield vaccine to COVAX, with the first batch going to Nepal, Tajikistan, Mozambique, and Bangladesh. The export can begin on November 23, following India's April ban on domestic vaccination.